Expanding brand awareness and access to HaluGen's Psychedelics Genetic Test Kit
Vancouver, British Columbia (Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE:
HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy
Vancouver, British Columbia (Newsfile Corp. - June 10, 2021) -
Entheon Biomedical Corp. Launches HaluGen s Psychedelics Genetic Test
HaluGen s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy
Vancouver, British Columbia (Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ( Entheon or the Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry s first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ( HaluGen ), and that it is now available for sale within Canada.
HaluGen s psychedelic pre-screening platform and DNA testing provides genetic, personal and familial insights to better inform one s psychedelic assisted therapy experience. By obtaining DNA test results, individuals and healthcare professionals are equipped with data to improve psychedelic assisted therapy patient care and reduce side effects and risk. Th